Lgm Pharma Expands U.s. Manufacturing, Bringing Total Investment To $15m Across Texas And Colorado Sites

LGM Pharma, a starring supplier of tailored API sourcing, statement analytical testing, and CDMO services for nan afloat supplier merchandise lifecycle, coming announced nan 2nd shape of its CDMO maturation strategy, committing an further $9 cardinal to its accommodation successful Rosenberg, Texas, and Colorado Springs, Colorado. The finance follows nan company’s antecedently announced $6 cardinal description successful Rosenberg successful 2025 and is designed to summation commercialized capacity, grow R&D capabilities, and support continued request for U.S.-based supplier merchandise manufacturing.

The Texas installation enhancements see a $4 cardinal finance to grow commercial-scale manufacturing suites for suppositories successful consequence to expanding customer and marketplace demand, including maturation successful women’s wellness products. The upgrades besides grow R&D capabilities to support formulation and scale-up for suppositories, solutions, suspensions, and semi-solids. The Rosenberg tract will stay afloat operational passim construction, pinch upgrades already underway.

In Colorado Springs, LGM Pharma will put $5 cardinal to grow commercialized manufacturing capacity for niche, high-value oral coagulated dose (OSD) products, including orally disintegrating tablets (ODTs). The installation has served arsenic nan company’s halfway of excellence for OSD development. The description , planned for completion this year, will support increasing request for home manufacturing. In 2024, nan world OSD CDMO marketplace was weighted astatine $43.65 billion, pinch North America accounting for astir 40.5 % of world OSD pharmaceutical manufacturing activity.

These multi-site investments totaling $15 cardinal bespeak our continued committedness to strengthening pharmaceutical proviso chains successful nan United States. Today’s pharma companies request partners that are some resilient and integrated crossed nan afloat merchandise lifecycle. By reinforcing home supplier merchandise manufacturing astatine nan downstream extremity of nan proviso chain, person to extremity markets, and leveraging our world API sourcing capabilities upstream, we create a balanced end-to-end model. This gives customers greater power and visibility arsenic they move products from improvement to commercialization.”

Prasad Raje, Chief Executive Officer of LGM Pharma

Earlier successful nan proviso chain, astatine nan supplier constituent stage, LGM Pharma supports 505(b)(2), NDA, and ANDA programs done a world web of much than 220 pre-qualified API manufacturers. By combining global drug constituent sourcing with expanded U.S. vanished dose improvement and manufacturing, nan institution provides integrated support crossed nan afloat supplier merchandise lifecycle.

Hamilton Lenox, Chief Commercial Officer of LGM Pharma, said nan company’s anterior Rosenberg upgrades from Phase I of nan description , including implementation of enhanced track-and-trace serialization systems and accrued accumulation volumes, are now complete. “We are executing this adjacent shape of description while keeping some accommodation afloat operational,” Lenox said. “Our teams are knowledgeable successful managing analyzable upgrades without sacrificing value aliases disrupting customer supply, which stay our apical operational priorities. Rather than overextending successful a azygous phase, we are executing these enhancements incrementally to grow capabilities and capacity while ensuring operational continuity. This attack allows america to fortify infrastructure, support customer growth, and standard successful consequence to marketplace demand.”

Companies processing 505(b)(2), NDA, aliases ANDA products, arsenic good arsenic those pinch commercialized branded aliases generic portfolios, are encouraged to research LGM Pharma’s API sourcing and expanded supplier merchandise manufacturing capabilities by visiting LGMPharma.com or gathering pinch institution executives at DCAT Week, March 23-26, 2026, successful New York City.